Drug Delivery

Novartis Ends BioArctic BrainTransporter Deal, Keeps $30M Upfront

STOCKHOLM – November 02, 2026 -- BioArctic AB will keep the full USD 30 million upfront payment from Novartis Pharma AG after Novartis terminated their Option, Collaboration and License Agreement, the Nasdaq Stockholm-listed company (BIOA B) announced.

Novartis drops the program, not the technology

The agreement was signed in August 2025. It covered a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed Novartis proprietary antibody. Novartis notified BioArctic that it decided to discontinue the program. According to BioArctic, the decision is unrelated to the BrainTransporter technology.

BioArctic books the remaining upfront payment as 2026 revenue

Because of the termination, BioArctic will recognize the remaining unrecognized portion of the USD 30 million upfront payment as revenue in 2026. The company did not disclose the size of that portion.

FDA Approves UCB's ZILBRYSQ Autoinjector for gMG; Launch Set for Q1 2027

Image
FDA Approves UCB's ZILBRYSQ Autoinjector for gMG; Launch Set for Q1 2027

Atlanta – October 16, 2026 -- The U.S. Food and Drug Administration (FDA) has approved a once-daily autoinjector for UCB's ZILBRYSQ (zilucoplan), with complete dose delivery in 99.8% of 449 administrations, UCB said. Commercial availability is expected in Q1 2027.

The device is cleared for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. UCB (Euronext Brussels: UCB) describes ZILBRYSQ as the first and only macrocyclic peptide C5 inhibitor approved as a self-administered, once-daily subcutaneous autoinjector for gMG in the U.S.

Autoinjector adds a second self-administration route alongside the prefilled syringe

Before this approval, ZILBRYSQ was available only as a self-administered prefilled syringe (PFS). The autoinjector automatically delivers a pre-defined dose when activated against the skin. Patients or their care partners now have two portable options.

Exosomes Market to Hit $2.25B by 2034 on 28.8% CAGR

Image
Exosomes Market to Hit $2.25B by 2034 on 28.8% CAGR

Pune, India – – September 23, 2026 -- The global exosomes market is set to grow nearly tenfold over the next decade, expanding from USD 230.55 million in 2025 to USD 2,250 million by 2034, according to a new analysis from Maximize Market Research. The projected 28.8% compound annual growth rate between 2026 and 2034 places exosome technology among the fastest-expanding segments in biopharmaceutical R&D.

Drug delivery pipelines drive commercial momentum

Pharmaceutical and biotechnology companies are expanding exosome-related pipelines as the nanosized extracellular vesicles gain traction as targeted carriers for drugs, proteins, and RNA. Rising investment in biotechnology and advances in isolation, characterization, and engineering technologies are pushing exosomes beyond research settings into drug development and regenerative medicine applications.